Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of gMG \[Myasthenia Gravis Foundation of America (MGFA) Class II-IVa\] at Screening~* Positive serology for acetylcholine receptor (AChR) autoantibodies~* QMG score ≥ 12 at Screening and Randomization~* No change in corticosteroid dose for at least 30 days prior to Randomization or anticipated to occur during the 12-week Treatment Period~* No change in immunosuppressive therapy, including dose, for at least 30 days prior to Randomization or anticipated to occur during the 12-week Treatment Period~Exclusion Criteria:~* Thymectomy within 6 months prior to Randomization or scheduled to occur during the 12 week Treatment Period~* History of meningococcal disease~* Current or recent systemic infection within 2 weeks prior to Randomization or infection requiring intravenous (IV) antibiotics within 4 weeks prior to Randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 0.1 mg/kg zilucoplan (RA101495) (Type: EXPERIMENTAL): None
- 0.3 mg/kg zilucoplan (RA101495) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).